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Abstract
There are an estimated 14,000 randomized trials published in chronic kidney disease. The most 
frequently reported outcomes are biochemical endpoints, rather than clinical and patient-reported 
outcomes including cardiovascular disease, mortality, and quality of life. While many trials have 
focused on optimizing kidney health, the heterogeneity and uncertain relevance of outcomes 
reported across trials may limit their policy and practice impact. The international Standardized 
Outcomes in Nephrology (SONG) Initiative was formed to identify core outcomes that are 
critically important to patients and health professionals, to be reported consistently across trials. 
We convened a SONG Implementation Workshop to discuss the implementation of core outcomes. 
Eighty-two patients/caregivers and health professionals participated in plenary and breakout 
discussions. In this report, we summarize the findings of the workshop in two main themes: 
socializing the concept of core outcomes, and demonstrating feasibility and usability. We outline 
implementation strategies and pathways to be established through partnership with stakeholders, 
which may bolster acceptance and reporting of core outcomes in trials, and encourage their use by 
end-users such as guideline producers and policymakers to help improve patient-important 
outcomes.
Keywords
core outcome sets; implementation; kidney disease; outcomes; patient-centered care; trials
To date, an estimated 14,000 randomized trials have been published in chronic kidney 
disease (CKD).1 Despite this substantive research effort and investment, patients with 
advanced CKD have mortality rates of up to 100 times higher than that of the general 
population,2,3 increased morbidity, and worse quality of life than patients with cancer and 
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other chronic diseases.4,5 There remains an urgent need for rigorous, high-quality trials to 
address these poor outcomes, with greater attention given to the selection, measurement, and 
reporting of outcomes in trials, to maximize their practice and policy impact and thus their 
value.6,7
The outcomes reported in trials are highly variable and measured in a plethora of ways, often 
without capturing those that are most meaningful for patients and clinicians for decision 
making.8 In a recent analysis of 362 trials in hemodialysis, 81 different outcomes were 
reported using 10,700 different measures.9 The 5 most frequently reported outcomes were 
all biochemical endpoints: phosphate, dialysis adequacy, anemia, inflammatory markers, and 
calcium.9 Mortality and cardiovascular disease were reported in only 20% and 12% of trials, 
respectively. Fatigue, consistently identified by patients as a critically important outcome, 
even above mortality,10–12 appeared in only 9% of trial reports.9 Also, selectively reporting 
outcomes that favor the intervention or omitting outcomes such as adverse events may be 
misleading and can potentially cause harm.13–15 A systematic review found that only 2% of 
trials of immunosuppressive agents in kidney disease reported a quality of life outcome and 
almost all reported effect estimates that favored the intervention.16
These problems in outcome reporting have also been recognized in other medical specialties 
and disease areas, including cancer, cardiology, chronic pain, dementia, dermatology, 
hematology, and otitis media,17–20 prompting efforts to establish core outcome sets to 
improve the relevance, certainty, and efficiency of trial-based evidence to reliably inform 
decision making. Core outcomes sets, as defined by the Core Outcome Measures in 
Effectiveness Trials (COMET), are “an agreed standardised set of outcomes that should be 
reported, as a minimum, in all clinical trials in specific areas of health or healthcare.”21 They 
may or may not be the primary outcome of trials, which are often selected because of their 
intervention-responsiveness and feasibility in terms of the resources required to achieve 
adequate statistical power. Core outcomes are identified through a consensus process to 
ensure they are critically important to patients and health professionals, with many initiatives 
drawing from the World Health Organization–endorsed framework developed by the 
Outcome Measures in Rheumatology (OMERACT) group, which was formed 1992.22–24
While core outcomes have the potential to improve the consistency and relevance of 
outcomes in trials,14,25,26 trialists have not consistently reported these outcomes when 
publishing results. The use of core outcomes has increased over time in trials in rheumatoid 
arthritis, whereas there has been limited change seen in other areas including gout and falls 
prevention.25–32 Barriers to implementation by trialists may include lack of awareness about 
core outcomes among trialists, resource constraints, lack of incentives, and complexities in 
measuring patient-reported outcomes.33,34 Without consistent reporting of these core 
outcomes, there is little scope for end-users such as guideline producers and policymakers to 
capitalize on their potential benefits. However, little remains known about the perspectives 
of stakeholders on the use of core outcomes, and frameworks and interventions for the 
implementation of core outcomes are lacking.21
COMET recommends that core outcome developers prepare a dissemination and 
implementation plan to target potential users of core outcomes.21 As part of the international 
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Standardized Outcomes in Nephrology (SONG) Initiative, which was founded in 2014 to 
establish core outcomes across the spectrum of CKD, we convened a workshop with 
patients, caregivers, and health professionals on the implementation of the core outcomes in 
trials in CKD. The workshop also included specific reference to core outcome sets that had 
been established at the time of the workshop (Figure 1a and b) including for patients 
receiving hemodialysis (fatigue, cardiovascular disease, vascular access function, 
mortality)9–12,35–38 and kidney transplant recipients (graft loss, cardiovascular disease, 
infection, life participation, cancer, mortality).39–42 These core outcome sets were developed 
using an evidence- and consensus-based process (systematic review, focus groups with 
nominal group technique, stakeholder interviews, an international Delphi Survey, and a 
consensus workshop) involving more than 1300 patients, caregivers, and health 
professionals from more than 70 countries in each stream (i.e., hemodialysis, kidney 
transplantation).10–12,37,38,40,41 The findings from the workshop will inform strategies and 
pathways for implementing core outcomes, with a focus on trials in nephrology.
SONG IMPLEMENTATION WORKSHOP
Participants and contributors
In total, 82 patients, caregivers, representatives from patient organizations (n =6), and health 
professionals (n=76)— including nephrologists, nursing and allied health professionals, 
researchers (including trialists), policy makers, and industry representatives—attended the 
workshop. Given the focus of the workshop on implementation of core outcomes, we invited 
patients and caregivers with experience in research or who held advocacy roles in consumer 
organizations (e.g., National Kidney Foundation, Patient-Centered Outcome Research 
Institute [PCORI] Home Dialyzors United, American Society of Nephrology /Kidney Health 
Initiative (ASN/KHI) Patient and Partnership Council, Polycystic Kidney Disease [PKD] 
International, PKD Foundation) and health professionals with leadership or advisory roles in 
professional societies (e.g., International Society of Nephrology, ASN, The Transplantation 
Society), funding agencies, research, regulatory, policy and industry organizations (including 
but not limited to: US National Institutes of Health, US Food and Drug Administration 
[FDA], US Centers for Disease Control, US Centers for Medicare and Medicaid Services). 
Journal editors, trialists and epidemiologists, guideline developers, and those involved in 
renal registries and trial networks were also invited to attend. The investigators who were 
unable to attend (n=84) contributed feedback on the workshop program and the draft 
workshop report by e-mail.
Workshop program and materials
The workshop was held on November 3, 2017, in New Orleans, during the 2017 ASN 
Kidney Week. A preworkshop survey and the workshop program and materials were sent to 
all investigators (n = 160) prior to the workshop. The preworkshop survey asked participants 
to describe how they accessed and used (or plan to use) core outcomes (if applicable); 
suggest strategies, mechanisms, and actions to promote the use of core outcomes; and 
describe or explain how they could support the implementation of core outcomes in their 
role. The initial responses (n=84) informed the questions and prompts for the workshop, 
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while providing the participants with an opportunity to reflect on the topic in preparation for 
the breakout discussion groups.
The program is provided in Supplementary Appendix S1 and was structured as follows: a 
presentation of the SONG Initiative to provide participants with an overview of the process; 
panel discussion reflecting the patient, professional society, industry, regulator, and trialist 
perspectives; and breakout discussions on the opportunities, barriers, and strategies for 
implementing core outcomes in CKD. The attendees were preassigned to one of the 8 
breakout groups, which involved 10 to 12 diverse stakeholders (patients or caregivers, 
physicians, regulators, funders, industry, researchers) to prompt broader and dynamic 
discussions. Each group was moderated by a facilitator, who used a question guide. After the 
plenary session, the chairs (J.C., B.M.) asked each group to provide a brief summary.
All the presentations and breakout group discussions were audiotaped and transcribed. The 
transcripts and survey responses were imported into HyperRESEARCH (Research-Ware 
Inc., version 3.0; Randolph, MA) software for analysis. The first author (A.T.) coded the 
transcript line-by-line and inductively identified concepts pertaining to the implementation 
of core outcomes. All participants were given 2 weeks to provide feedback on the draft 
workshop report and to confirm that the findings reflected the full range of their 
perspectives. Any additional comments were synthesized and included in the final report.
SUMMARY OF WORKSHOP DISCUSSION
The participants’ perspectives on implementing core outcomes in trials in kidney disease 
were summarized in 2 overarching themes: socializing the concept (to make the definition 
and purpose of core outcomes acceptable or considered the norm in the nephrology 
community), and demonstrating feasibility and usability, which are described in the 
following section. Selected quotations to support each theme are provided in Table 1. A 
schema depicting the themes is shown in Figure 2. Key strategies and recommendations for 
implementing core outcomes are outlined in Table 2.
Socializing the concept
“Socializing the concept, explaining to everybody why it’s important, making sure that all of 
our colleagues understand the advantage of why including core outcomes in clinical trials 
might actually help us get somewhere quite different in nephrology in a shorter period of 
time.” (Health professional).
Articulating a compelling case for change.—The implementation of core outcomes 
requires efforts by the community (including professional and patient organizations) to 
convince health professionals and patients of the “advantages” of core outcomes—“half our 
colleagues don’t even know they have to do clinical trials, let alone why we need to do 
outcomes” (health professional). They urged that “unless there is some change, some 
improvement, then we’re stuck” (health professional). “Connecting the dots” for everyone 
would help them realize the lack of evidence about what is important to patients and 
clinicians—“we don’t have answers to questions because we’ve been mixed up, we don’t 
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have the outcomes that everybody agrees to” (health professional)—and be persuaded of the 
pressing need for core outcomes.
Participants suggested emphasizing that a core outcome set “ensures consistency across 
studies, allows us to compare things so we have more knowledge, facilitates the uptake of 
results, reduces confusion, and ensures that we have relevance—to clinicians, patients, 
regulators, in a very real way” (health professional). Trials would capture outcomes that 
have a direct impact on patients—“pain, infection, anxiety … all these things not included in 
trials,” and ultimately “accelerate quality research” (patient). To have core outcomes 
available would “save” trialists from “thrashing about looking for an outcome because it’s 
been devised” (health professional).
Core outcomes could identify “unforeseen consequences” of an intervention, even if there 
was “not a direct link to the intervention” and that this could be “leveraged.” Health 
professionals remarked: “we all get sort of strange and unexpected findings; unless you 
measure it, or report it, you don’t know.” Also, it was noted that while an effect may not be 
seen in a single trial, consistent reporting of core outcomes would be important “because 
when you do a meta-analysis, perhaps you could get a positive result” (health professional).
Clarifying the intent and meaning.—Coherent communication about the definition and 
purpose of core outcomes was needed because the concept could be new and unfamiliar to 
some patients and health professionals. Researchers were concerned about the feasibility and 
relevance of using core outcomes as primary outcomes, and that they may not be responsive 
to the study intervention. Thus, it was important to explain that core outcomes “need not be 
the primary outcome,” rather they were to be “collected and reported as part of that study 
even if they are not the primary outcome,” because they were critically important to 
stakeholders. They suggested to frame the use of core outcomes as an “add on”: in other 
words, “you come up with your own outcomes, that are nuanced towards your intervention, 
but then you add these extra [core] outcomes so you can at least say it made no difference to 
fatigue, cardiovascular disease as far as our trial is concerned” (health professional). Also, to 
reiterate that core outcomes were included on the basis of their importance to patients and 
health professionals, irrespective of the intervention and the size and duration of the trial: 
“it’s about research to inform decision-making rather than the trialists finding something 
positive or responsive to their interventions” (health professional).
Ensuring trust and credibility.—Recognizing that the core outcomes were 
“internationally derived, used respected methodology, accredited, peer-reviewed, and non-
commercial” (patient) would promote trust and uptake. Researchers would need to have 
confidence in the consensus process, international and cross-cultural applicability, and 
reassurance that patients were involved in a meaningful and substantial way. There had to be 
consistency in the definition and interpretation of outcomes (and outcome measures), and 
validation and endorsement by relevant groups would strengthen credibility. Part of “selling 
core outcomes” entailed making transparent the rigor of the process, explaining “how did we 
get to here, who made these decisions, are they valid?” (health professional).
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Fostering community ownership.—Stakeholder groups (e.g., payers, regulators, 
industry organizations, trialists, and consumers) had to be engaged early and “buy in” to the 
process, to strengthen impetus for implementing core outcomes: “the big danger is 
dissemination by lamination. It’s got to come from the ground up. People have got to own 
the message” (health professional). Participants suggested to “tailor the message to people, 
and to get the attention of patients through networks, and have patients tell the patients, we 
as the individual as well as our colleagues should own the message and distribute it from the 
ground up” (health professional).
Health professionals recognized that conflicting agendas between stakeholder groups may 
be potential barriers to implementation: “pharmaceutical companies have agendas to bring 
drugs on the market as quickly as possible and to generate profits and sometimes we are not 
in agreement that the outcomes chosen are necessarily in alliance with what might be the 
priorities of patients and health care providers.” Further efforts were needed to “spread it 
[core outcomes] into [industry] organizations” (health professional).
Participants posited that “competition” among researchers and societies could be a barrier to 
“accepting [the core outcomes] because they feel they weren’t at the table” (health 
professional). They thought it may be challenging to “get other groups (non-nephrology 
societies)” to agree on the harmonization of definitions for core outcomes and measures 
identified, for example, cardiovascular disease (cardiology), and agreed that “heavy hitters 
like oncology and cardiology needed to be on board and be in parallel doing similar things” 
(health professional) to gain broader acceptance and uptake.
Modeling on exemplars of culture shift.—Highlighting prior successes of 
implementing similar or related initiatives in trials was identified as a strategy for promoting 
the uptake of this newer concept of core outcomes. Participants referenced cardiology 
“where they had clear definitions of their key outcomes that they routinely use that have 
really helped to move the field forward” (health professional). The requirements to register 
trials, obtain Institutional Review Board approval, and report according to the Consolidated 
Standards of Reporting Trials (CONSORT) were given as examples of “very significant 
brain shifts that have now been adopted very widely” (health professional) despite initial 
concerns of the added burden these would impose.
Reinforcing with authoritative advisory support.—Mandating or insisting on the use 
of core outcomes in grant applications, journal publications, and regulatory approvals would 
force researchers “to toe the line” with efforts focused “further upstream” expected to be 
more effective. Trial registries (e.g., ClinicalTrials.gov) and funding agencies (e.g., National 
Institutes of Health [NIH]) would be the “stronger levers” for implementation because the 
use of core outcomes would be considered at the design phase of the trial. Trial registries 
could list the core outcomes to provide a “systematic way of making trialists think about it 
before they start the trial” (health professional). Trial networks were also identified as a 
potential opportunity to provide trialists with guidance on using core outcomes. Explicit 
support from regulators (e.g., US Food and Drug Administration [FDA], European 
Medicines Agency [EMA]) would be a catalyst for implementation. Even if regulators 
“suggested” the use of core outcomes, sponsors would feel compelled to adopt them: “they 
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will walk away with a strong message—’we have to do it, we can’t not do it’” (health 
professional). There were concerns that mandating the use of core outcomes may be “too 
prescriptive” and that researchers could be encouraged rather than forced to use core 
outcomes; whereas others argued that “there must be not a carrot but a stick to implement 
it.”
Demonstrating feasibility and usability
“We don’t want them misused or used inappropriately, we want some tools for 
implementation” (health professional).
Providing proof of concept.—Empiric data to confirm that the “quality of studies 
improves after the implementation,” of core outcomes would “show that it’s not just a 
theoretical concept” (health professional), and thus provide a strong reason for their use. 
Pilot testing core outcome sets in some trials was suggested. Another idea was to “go back 
to some trials, pharmaceutical trials through to some registry trials, to see what the effect 
would be if we have these core outcomes and test whether they work or not … to 
demonstrate benefit from having done this” (health professional). For pragmatic trials, some 
health professionals suggested to evaluate “what would we have had to have done, what 
would the benefits be” if core outcomes were used.
Readily accessible and visible.—Making core outcomes prominent by “publishing in 
journals, and also [presenting them] in workshops and educational activities” (health 
professional) would support uptake. Providing direct access to core outcomes (e.g., on the 
website) meant researchers could easily “download” the core outcome set when writing 
grant applications or trial protocols. The core outcomes and their respective measures had to 
be “readily available in different formats where it’s easy to pluck out from the web and use 
within your own structure of clinical trials” (health professional). Participants suggested 
submitting core outcomes to relevant organizations such as the US National Quality Forum 
or the NIH Common Data Elements repository because researchers “go looking for 
measures—they go there and pull it off the shelf” (health professional).
Maximizing operationalizability.—Core outcomes require firmly established definitions 
and measures, otherwise they would be too ambiguous to implement. For example, 
cardiovascular disease was a broad outcome domain (e.g., could include myocardial 
infarction, sudden cardiac death) and could be measured in multiple ways. A core outcome 
had to be stable over a reasonable time frame and be “definitive because the trials we are 
doing now, another one is done in 10 years, 15 years, some of these outcomes change, of 
course mortality cannot change, before we call them core outcomes, we should have a very 
good crystal clear definition that doesn’t change” (health professional). It was important to 
specify “how you ask the question, who delivers it.”
Being able to integrate core outcomes into case report forms and “documented” in electronic 
health records and databases using classification codes, for example the International 
Classification of Diseases, would facilitate efficient data collection on core outcomes in 
trials. “Micro-specification” of core outcomes would enable researchers to enter and extract 
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data on core outcomes efficiently and in a reproducible way. This could be challenging for 
patient-reported outcomes such as fatigue: “to define them in a very granular way is 
absolutely excruciating” (health professional). Health professionals noted the increasing 
number of trials using quality-adjusted life years in cost-effectiveness analyses, and thus 
advocated that quality of life domains had to be “built in at the very beginning of study 
design.”
Training researchers in how to use core outcome measures in trials would “speed up the 
implementation,” and this could be delivered through tutorials and resources: “if there is a 
centralized way that you can go to the website to see how to administer the tool [e.g., paper 
versus electronic tablet], then you are more likely to have some standardization of 
measurement” (health professional). Systemic lupus erythematous was given as an example 
where researchers had to be trained to assess and score disease activity using measures such 
as the SLE Disease Activity Index (SLEDAI) and British Isles Lupus Activity Group 
(BILAG): “we all deliver it in the same way, and actually we all use the same program to 
analyze it so it does introduce uniformity” (health professional).
Allowing adaptation when necessary.—Health professionals identified circumstances 
in which core outcomes could not be feasibly or appropriately implemented. Pragmatic or 
registry trials typically used “data that’s already being collected” as part of routine care or in 
registries, which may not currently include core outcomes and thus could not be feasibly 
included in such trials. An “opt out” approach could be considered whereby core outcomes 
would be “strongly encouraged and trialists would be expected to use them,” and researchers 
requested to provide a justification to seek exemption (e.g., from funders, trial registration 
organizations) from using core outcomes. In grant applications, trialists could indicate 
whether core outcomes have been included and if not to provide the reason, similar to tick 
boxes used (e.g., to indicate whether the study had equal representation of sexes, or 
Institutional Review Board approval). However, they noted that “to come down really hard is 
going to be difficult but we are going to have flexibility in the appropriateness in the 
implementation of these, but then it’s very hard to call them ‘core’” (health professional).
Guaranteeing minimal burden, cost, and consequence.—Health professionals 
emphasized that core outcomes had to be “measured relatively easily, simply and cheaply.” 
Imposing an undue “extra burden” to trials would be a barrier to implementation and 
“people would resent it.” In particular, trials “where you don’t have an a priori concern or 
it’s not your efficacy outcome, you don’t want to attach a lot of burden” in measuring the 
core outcomes. They cautioned that increased cost and resources to include core outcomes 
may potentially “inhibit the conduct of high quality trials, which would be counter to what 
we are trying to do.” Objections to the use of core outcomes were expected if they were seen 
as “a disincentive to running trials because it’s an extra bureaucratic layer they feel they 
have to jump through.” The resource implications of implementing core outcomes, 
particularly in low-income countries, had to be considered. Also, core outcomes should not 
“distract people, including the patients, from what the trial is about.”
Health professionals also recognized that in the current academic environment, “we are 
perpetuating research careers and science that is overdriven by biomarkers and surrogates, 
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because they are a great track record, [you get] a lot of publications” and early career 
researchers in particular may not be able to invest the extra resources and time to measure 
and report core outcomes in their studies.
Incentives for implementing core outcomes had to be “nonpunitive” such that providers or 
sponsors would not be “punished” based on their data pertaining to core outcomes. For 
example, with the increased use of extended criteria kidneys for transplantation, some health 
professionals observed that the commencement of dialysis posttransplant (due to delayed 
graft function) was sometimes deliberately delayed in order to achieve center-based 
performance indicators and targets. As a consequence, transplant recipients became volume 
overloaded for a longer period of time, which could lead to serious adverse effects. They 
remarked that health professionals may fear “that if core outcomes were going to get 
mandate, it’s going to be used against them, they will be called bad citizens” and urged that 
regulators (e.g., CMS) would have to guarantee that “negative or neutral results are not 
going to affect their registration.”
Integrating into infrastructure.—Embedding core outcomes in registries, 
epidemiological cohort studies, and routine care(i.e., as quality indicators) would 
subsequently facilitate their uptake particularly in pragmatic trials “where we are trying to 
minimize the burden of data collection and use existing infrastructure.” Registries were 
somewhat “messy” with variable definitions and measures used for many outcomes 
including kidney function, which could be ascertained using different equations (e.g., 
Modification of Diet in Renal Disease, Cockcroft Gault). Health professionals suggested to 
“embed core outcomes in registries so that every six months patients are asked about fatigue, 
myocardial infarction, stroke, the data are all automatically recorded, its automatically in the 
electronic system” (health professional). Having core outcomes embedded into routine 
clinical care could then be leveraged as part of clinical trials. Also, “if we can actually 
integrate these [core outcomes] into clinical care, it’s going to be easier for regulatory 
agencies to access them. If you collect it for post-market outcome assessment, it’s a lot 
easier for industry to collect if it’s something that’s captured as part of routine clinical care.”
DISCUSSION
A multipronged approach to socialize the concept and demonstrate the feasibility and 
usability of core outcomes in nephrology studies could motivate trialists and facilitate the 
implementation of core outcomes in trials. This would involve advocating the need for 
improved consistency and relevance of research and addressing potential skepticism by 
ensuring trust in the process of establishing core outcomes, buy-in from stakeholders, 
demonstrating the impact of similar initiatives, and securing support from authoritative 
bodies. The core outcomes should be readily accessible, clearly defined with validated 
measures, applicable, and of minimal burden to implement in trials internationally. 
Particularly for novel trial designs such as registry or pragmatic trials, core outcomes would 
need to be integrated into clinical care infrastructures or research registries.
Publishing core outcomes, communicating with relevant stakeholders groups, and involving 
potential users in the development process, have been identified by core outcome developers 
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as strategies for dissemination and implementation.21 Our workshop discussions indicate the 
need to make clear the goal and definition of core outcomes, framed in such a way that 
would be acceptable to researchers, and to address concerns about feasibility and 
applicability. Core outcomes are critically important to patients and clinicians for decision 
making and should be considered for use as primary outcomes where possible, otherwise 
they should be added and tracked with primary outcomes that trialists have selected to be 
relevant to their intervention. In addition, core outcomes have potential benefits for other 
end-users such as guideline producers and policymakers.
Strategies to promote uptake of core outcomes can be conceptualized as “push” (directly 
encouraging trialists to collect and report data on core outcomes) or “pull” (encouraging 
end-users to highlight the need for these outcomes so that they can be used to benefit 
patients, such as in practice guidelines or quality measures or both). Likely both types of 
strategies will be required to effect meaningful change.
Partnerships with stakeholders and relevant organizations are needed to support and to 
expedite the uptake of core outcomes. COMET has identified trialists, trial registries, 
funders, research registries, journals, and systematic review organizations as having a role in 
the implementation of core outcomes.21 In addition, participants in the workshop recognized 
that professional societies and consumers (i.e., patients, caregivers) could also help to 
educate and advocate for the use of core outcomes. Patient organizations liaise with 
clinicians, academic, industry, and government and regulatory agencies to promote research.
43
 Patients and patient organizations also increasingly participate in guideline production 
and thus are strongly positioned to support the implementation of core outcomes by 
appealing to both trialists and end-users.
There have been a few initiatives aimed at promoting the uptake of core outcomes in 
research proposals. The Standard Protocol Items: Recommendations for Interventional Trials 
(SPIRIT) checklist recommends to use a common set of key outcomes in trials to “deter 
selective reporting of outcomes and to facilitate comparisons and pooling of results across 
trials in a meta-analysis.”44 In the UK, the National Institute for Health Research guidance 
notes for applicants submitting a proposal for funding states that “where established Core 
Outcomes exist they should be included amongst the list of outcomes unless there is good 
reason to do otherwise”45 and advises applicants to refer to the COMET database of core 
outcomes. While there is currently no regulatory mandate specific to implementing core 
outcomes, regulators are seeking increased clarity about what outcomes matter to patients 
that could be submitted for review and potential marketing approval, and there have been 
initiatives to improve outcome reporting in trials. The US NIH recommends the use of 
common data elements in NIH-funded projects or registries.46 FDA and EMA have 
produced guidance documents on the use of patient-reported outcome measures in trials. 
EMA and FDA can issue a qualification opinion on the acceptability of a specific use of a 
method (including outcome measures) for use in trials.47,48 These examples indicate that 
regulatory agencies or policy organizations have a potential role in supporting the 
implementation of core outcomes in trials.
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Despite these promising initial efforts, the potential benefits of adopting core outcomes do 
not appear to have been fully recognized by guideline producers or other end-users such as 
policymakers. Further efforts are needed to develop and evaluate training resources (e.g., 
tools, tutorials) to collect and report data on core outcomes, as well as educate trialists and 
end-users about their benefits for patients. Table 2 outlines implementation strategies and 
pathways covering education, dissemination, and resources and infrastructure for efficient 
operationalization of core outcomes, which may be established through partnership with 
stakeholders.
In summary, core outcome sets are being developed to improve the relevance, consistency, 
and reliability of trial evidence to inform decision making and to systematically include the 
patient perspective. However, overcoming potential barriers to uptake necessitates 
partnerships with key stakeholders (including trialists and end-users) to “socialize” the 
concept of core outcomes and demonstrate that they can be feasibly applied in trials. Also, 
efforts will be needed to ensure ongoing monitoring and evaluation of the use and impact of 
core outcomes.
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Figure 1 |. Core outcome sets for Standardized Outcomes in Nephrology (SONG).
Outcome sets for (a) SONG-Hemodialysis (SONG-HD) and (b) SONG–Kidney 
Transplantation (SONG-Tx) are shown.
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Figure 2 |. 
Thematic schema.
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ld
 p
ot
en
tia
lly
 p
ro
m
ot
e 
th
is.
 (H
ea
lth
 pr
ofe
ssi
on
al)
In
 so
m
e 
fu
nd
in
g 
ag
en
ci
es
, t
he
 p
ro
gr
am
 o
ffi
ce
r p
ar
tic
ip
at
es
 a
nd
 o
v
er
se
as
 p
ro
to
co
l d
ev
el
op
m
en
t a
nd
 th
at
 in
di
v
id
ua
l c
ou
ld
 in
sis
t o
n 
th
e 
us
e 
of
 
st
an
da
rd
iz
ed
 o
ut
co
m
es
.
(H
ea
lth
 pr
ofe
ssi
on
al)
1,
2,
3,
4,
5,
6,
7,
8
Pr
ov
id
in
g 
pr
oo
f o
f c
on
ce
pt
D
em
on
st
ra
tin
g 
fe
as
ib
ili
ty
 a
nd
 u
sa
bi
lit
y
Th
er
e’
s g
oi
ng
 to
 b
e 
so
m
e 
sk
ep
tic
ism
 th
at
 th
es
e 
co
re
 o
ut
co
m
e 
m
ea
su
re
s a
re
 g
oi
ng
 to
 w
o
rk
. I
 w
o
n
de
r i
f w
e 
co
ul
d 
go
 b
ac
k 
to
 so
m
e 
tri
al
s a
nd
 ju
st 
de
m
on
str
at
e 
w
ith
in
 a
 n
um
be
r o
f d
iff
er
en
t t
yp
es
 o
f t
ria
ls,
 so
m
e 
ph
ar
m
ac
eu
tic
al
 tr
ia
ls 
th
ro
ug
h 
to
 so
m
e 
re
gi
str
y 
tri
al
s, 
w
ha
t w
o
u
ld
 b
e 
th
e 
ef
fe
ct
 if
 w
e 
ha
v
e 
th
es
e 
co
re
 o
ut
co
m
es
, a
nd
 so
rt 
of
 te
st 
w
he
th
er
 th
ey
 d
o 
w
o
rk
 o
r n
ot
. (H
ea
lth
 pr
ofe
ssi
on
al)
If 
yo
u 
ca
n 
sh
ow
 th
at
 th
e 
qu
al
ity
 o
f s
tu
di
es
 im
pr
ov
es
 a
fte
r t
he
 im
pl
em
en
ta
tio
n 
of
 th
es
e 
co
re
 o
ut
co
m
es
, t
ha
t’s
 a
 n
o 
br
ai
ne
r. 
(H
ea
lth
 pr
ofe
ssi
on
al)
M
ay
be
 d
o 
pi
lo
t t
es
tin
g,
 if
 w
e 
co
m
e 
ou
t w
ith
 a
 fi
rs
t s
et
 o
f o
ut
co
m
es
, l
et
’s
 d
o 
so
m
e 
pi
lo
t t
es
tin
g,
 a
 fe
w
 d
iff
er
en
t t
ria
ls,
 sm
al
l g
ro
up
s o
f p
at
ie
nt
s, 
an
d 
pr
ov
e 
to
 o
ur
se
lv
es
 th
at
 w
ha
t w
e 
ch
os
e 
m
ak
es
 s
en
se
. 
(H
ea
lth
 pr
ofe
ssi
on
al)
1,
4,
5,
6
A
cc
es
sib
le
, a
pp
lic
ab
le
, a
nd
 
pr
ac
tic
al
H
av
e 
[co
re 
ou
tco
me
s] 
rea
dil
y a
v
ai
la
bl
e 
in
 d
iff
er
en
t f
or
m
at
s w
he
re
 it
’s
 e
as
y 
to
 p
lu
ck
 o
ut
 [o
f] 
the
 w
eb
 an
d u
se
 w
ith
in 
yo
ur
 ow
n
 s
tr
uc
tu
re
 o
f y
ou
r 
cl
in
ic
al
 tr
ia
ls 
so
 if
 it
’s
 e
le
ct
ro
ni
c 
th
at
 y
ou
 c
ou
ld
 h
av
e 
a 
so
rt
 o
f a
n 
ap
p 
or
 a
n 
iP
ad
 b
u
t y
ou
 w
o
u
ld
 a
lso
 h
av
e 
th
e 
pa
pe
r v
er
sio
ns
 av
ai
la
bl
e,
 y
ou
 w
o
u
ld
 
al
so
 h
av
e 
th
e 
va
rio
us
 d
iff
er
en
t f
or
m
at
s a
v
ai
la
bl
e,
 fo
r i
m
pl
em
en
ta
tio
n 
of
 th
es
e 
ou
tc
om
es
. (H
ea
lth
 pr
ofe
ssi
on
al)
If 
yo
u 
ar
e 
go
in
g 
to
 a
ll 
th
e 
ef
fo
rt,
 o
f a
ct
ua
lly
 d
ev
el
op
in
g 
th
e 
to
ol
, s
ub
m
it 
th
e 
m
ea
su
re
 to
 a
 m
ea
su
re
 o
rg
an
iz
at
io
n 
lik
e 
th
e 
N
at
io
na
l Q
ua
lity
 Fo
ru
m
. 
W
he
n 
pe
op
le
 lo
ok
 fo
r s
tu
ff,
 th
ey
 a
ct
ua
lly
 g
o 
lo
ok
 th
er
e,
 th
e 
go
v
er
n
m
en
t g
oe
s l
oo
ki
ng
 th
er
e,
 o
th
er
s g
o 
lo
ok
in
g 
th
er
e 
fo
r m
ea
su
re
, b
ec
au
se
 it
’s
 a
ll 
v
al
id
at
ed
 so
 if
 y
ou
 w
an
te
d 
to
 u
se
 y
ou
 c
an
 p
ul
l i
t o
ff 
th
e 
sh
el
f. 
(H
ea
lth
 pr
ofe
ssi
on
al)
1,
2,
3,
4,
5,
6,
7,
8
M
ax
im
iz
in
g 
op
er
at
io
na
liz
ab
ili
ty
Th
ey
 sh
ou
ld
 b
e 
de
fin
iti
v
e 
be
ca
us
e 
th
e 
tri
al
s t
ha
t w
e 
do
 a
re
 d
on
e 
no
w
,
 
an
o
th
er
 o
ne
 is
 d
on
e 
in
 1
0 
ye
ar
s, 
15
 y
ea
rs
, s
om
e o
f t
he
se
 o
ut
co
m
es
 ch
an
ge
 
…
 
be
fo
re
 w
e 
ca
ll 
th
em
 c
or
e 
ou
tc
om
es
, w
e 
al
so
 h
av
e 
a 
v
er
y 
go
od
 c
ry
sta
l c
le
ar
 d
ef
in
iti
on
 th
at
 d
oe
sn
’t 
ch
an
ge
. (H
ea
lth
 pr
ofe
ssi
on
al)
W
e 
al
m
os
t a
ll 
us
e 
CR
Fs
 n
ow
 a
n
d 
it’
s g
en
er
at
ed
 c
od
e 
so
 w
ha
te
v
er
 d
at
ab
as
e 
yo
u 
ar
e 
go
in
g 
to
 b
e 
ab
le
 to
 u
se
, y
ou
 c
ou
ld
 ju
st 
use
, “
he
re 
yo
u a
re,
 
he
re
’s
 o
ur
 k
ey
 c
or
e 
ou
tc
om
es
” 
an
d 
if 
yo
u 
ar
e 
go
in
g 
to
 d
o 
th
is 
tri
al
, i
f y
ou
 sa
id
 I’
ve
 ju
st 
go
t th
e c
od
e f
or 
yo
u, 
he
re 
it i
s, i
t is
 ea
sy.
 
(H
ea
lth
 
pr
of
es
sio
na
l)
Is
 th
er
e 
go
in
g 
to
 b
e 
so
m
e 
ki
nd
 o
f t
ut
or
ia
l o
r s
om
et
hi
ng
? 
If 
th
er
e 
is 
a 
ce
nt
ra
liz
ed
 w
ay
 th
at
 y
ou
 c
an
 g
o 
to
 th
e 
w
eb
sit
e 
of
 h
ow
 to
 a
dm
in
ist
er
 th
e 
to
ol
, 
th
en
 y
ou
 a
re
 m
or
e 
lik
el
y 
to
 h
av
e 
so
m
e 
st
an
da
rd
iz
at
io
n 
of
 m
ea
su
re
m
en
t r
at
he
r t
ha
n 
sa
yi
ng
, w
el
l m
ea
su
re
 th
is,
 th
is 
an
d 
th
is,
 h
ow
 a
re
 y
ou
 g
oi
ng
 to
 
m
ea
su
re
 it
, I
 a
sk
 m
y 
co
or
di
na
to
rs
 to
 d
o 
ce
rta
in
 m
ea
su
re
m
en
ts,
 a
nd
 th
ey
 a
re
 g
oi
ng
 to
 d
o 
it 
5 
di
ffe
re
nt
 w
ay
s u
nl
es
s I
 tr
ai
n 
th
em
 a
nd
 sa
y 
th
is 
is 
th
e 
w
ay
.
 
(H
ea
lth
 pr
ofe
ssi
on
al)
Cr
ea
te
 a
 m
ic
ro
 sp
ec
ifi
ca
tio
ns
 m
an
ua
l s
o 
if 
so
m
eo
ne
 a
ct
ua
lly
 w
an
te
d 
to
 im
pl
em
en
t t
hi
s, 
it 
w
o
u
ld
 b
e 
do
ne
 c
on
sis
te
nt
ly
.
 
(H
ea
lth
 pr
ofe
ssi
on
al)
Yo
u
 c
an
 h
av
e 
ca
rd
io
v
as
cu
la
r d
ise
as
e 
as
 y
ou
r o
ut
co
m
e 
bu
t w
ha
t e
x
ac
tly
 is
 y
ou
r c
ar
di
ov
as
cu
la
r d
ise
as
e 
th
at
 y
ou
 a
re
 ta
lk
in
g 
ab
ou
t, 
so
 th
at
 [i
s] 
gr
an
ul
at
or
y.
 
Th
at
 is
 a
n 
iss
ue
 fo
r f
at
ig
ue
 a
s w
el
l. 
So
 if
 p
eo
pl
e 
do
 re
po
rt 
ca
rd
io
v
as
cu
la
r d
ise
as
e,
 th
ey
 a
re
 u
sin
g 
th
e 
pa
tie
nt
’s
 IC
D
-9
 co
de
s, 
IC
D
-1
0 
co
de
s. 
(H
ea
lth
 pr
ofe
ssi
on
al)
1,
2,
3,
4,
5,
6,
7,
8
A
llo
w
in
g 
ad
ap
ta
tio
n 
w
he
n 
n
ec
es
sa
ry
W
e 
ar
e 
m
o
v
in
g 
to
 m
or
e 
ef
fic
ie
nt
 tr
ia
l c
on
du
ct
 w
he
re
 w
e 
ar
e 
lo
ok
in
g 
to
 u
se
 d
at
a 
th
at
’s
 a
lre
ad
y 
be
in
g 
co
lle
ct
ed
 a
s m
uc
h 
as
 p
os
sib
le
 a
nd
 in
 th
at
 
sit
ua
tio
n 
th
er
e’
s n
o 
w
ay
 w
e 
go
 b
ac
k 
an
d 
re
de
fin
e 
th
e 
ou
tc
om
es
, s
o 
w
e 
ne
ed
 to
 a
llo
w
 s
o
m
e 
fle
x
ib
ili
ty
 in
 te
rm
s o
f h
ow
 w
e 
u
se
 o
u
tc
om
es
. (H
ea
lth
 
pr
of
es
sio
na
l)
[W
e] 
are
 go
ing
 to
 ha
v
e 
to
 h
av
e 
fle
x
ib
ili
ty
 in
 th
e 
ap
pr
op
ria
te
ne
ss
 in
 th
e 
im
pl
em
en
ta
tio
n 
of
 th
es
e,
 b
u
t t
he
n 
it’
s v
er
y 
ha
rd
 to
 c
al
l t
he
m
 c
or
e.
 (H
ea
lth
 
pr
of
es
sio
na
l)
Th
e 
co
re
 o
ut
co
m
e 
m
ea
su
re
 sh
ou
ld
 b
e 
fle
x
ib
le
, a
nd
 p
ra
gm
at
ic
 e
no
ug
h,
 w
e 
ha
v
e 
to
 a
llo
w
 s
o
m
e 
fle
x
ib
ili
ty
 a
nd
 le
av
e 
it 
to
 so
m
e 
de
gr
ee
 to
 th
e 
lo
ca
l 
pr
ac
tic
e,
 h
ow
 to
 m
ea
su
re
 s
om
et
hi
ng
, b
u
t i
t s
til
l h
as
 to
 b
e 
a 
sta
nd
ar
di
ze
d 
de
fin
iti
on
. (H
ea
lth
 pr
ofe
ssi
on
al)
1,
2,
3,
7
G
ua
ra
nt
ee
in
g 
m
in
im
al
 b
u
rd
en
, c
os
t 
an
d 
co
ns
eq
ue
nc
e
If 
yo
u’
re
 in
 a
 se
tti
ng
 w
he
re
 y
ou
 d
on
’t 
ha
v
e 
a 
pr
io
ri 
co
n
ce
rn
 o
r 
it’
s n
ot
 y
ou
r e
ffi
ca
cy
 o
ut
co
m
e,
 o
bv
io
us
ly
 y
ou
 d
on
’t 
w
an
t t
o 
at
ta
ch
 a
 lo
t o
f b
u
rd
en
 
in
 tr
yi
ng
 to
 c
ha
ra
ct
er
iz
e 
th
es
e 
en
dp
oi
nt
s. 
(H
ea
lth
 pr
ofe
ssi
on
al)
1,
2,
3,
4,
5,
6,
7
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Th
em
e
Qu
ota
tio
ns
G
ro
u
p 
ID
W
e 
ar
e 
lo
ok
in
g 
at
 tr
ia
ls 
th
at
 c
an
 b
e 
do
ne
 a
ro
un
d 
th
e 
w
o
rld
 a
nd
 th
e 
re
so
ur
ce
s i
m
pl
ic
at
io
ns
 o
f w
ha
t w
e 
ar
e 
as
ki
ng
 p
eo
pl
e 
to
 d
o 
in
 tr
ia
ls 
th
at
 m
ay
 b
e 
fo
r e
x
am
pl
e 
ru
n 
in
 lo
w
-in
co
m
e 
co
un
tri
es
 w
ith
 v
er
y 
lim
ite
d 
re
so
ur
ce
s, 
ev
er
y 
ad
di
tio
na
l t
hi
ng
 th
at
 h
as
 to
 b
e 
co
lle
ct
ed
 h
as
 im
po
rta
nt
 c
os
t a
nd
 
re
so
u
rc
e 
im
pl
ic
at
io
ns
, t
ha
t m
ay
 in
hi
bi
t t
he
 c
on
du
ct
 o
f h
ig
h-
qu
al
ity
 tr
ia
ls 
w
hi
ch
 w
o
u
ld
 b
e 
co
un
te
r t
o 
w
ha
t w
e 
ar
e 
try
in
g 
to
 d
o.
 (H
ea
lth
 
pr
of
es
sio
na
l) 
Th
ere
’s 
go
t to
 be
 so
me
 ki
nd
 of
 no
np
un
itiv
e 
in
ce
nt
iv
e 
…
 h
ow
 c
an
 r
eg
ul
at
or
s p
ro
te
ct
 th
em
 fr
om
 n
eg
at
iv
e 
o
r 
n
eu
tr
al
 re
su
lts
 [f
or
 th
e 
co
re
 o
u
tc
om
es
], 
it’
s n
ot 
go
ing
 to
 af
fe
ct
 y
ou
r r
eg
ist
ra
tio
n?
 (H
ea
lth
 pr
ofe
ssi
on
al)
Th
e 
iss
ue
 o
f c
os
t, 
an
d 
co
st 
no
t ju
st 
in 
ter
ms
 of
 fin
an
ci
al
 te
rm
s, 
bu
t c
os
t i
n 
tim
e 
w
ith
 in
te
ra
ct
io
n 
w
ith
 p
at
ie
nt
s a
nd
 th
e 
bu
rd
en
 o
f i
m
pl
em
en
tin
g 
so
m
e 
m
ea
su
re
s 
an
d 
re
po
rti
ng
 d
at
a.
 (H
ea
lth
 pr
ofe
ssi
on
al)
O
ne
 c
ha
lle
ng
e 
is 
th
e 
te
ns
io
n 
be
tw
ee
n 
try
in
g 
to
 b
e 
un
ifo
rm
 a
cr
os
s a
ll 
tri
al
s a
nd
 in
cl
ud
e 
th
is 
co
re
 se
t a
cr
os
s a
ll 
tri
al
s b
u
t n
ot
 h
av
e 
it 
ov
er
w
he
lm
 th
e 
re
al
 g
oa
l o
f a
 p
ar
tic
ul
ar
 tr
ia
l…
 so
 it
 d
oe
sn
’t 
ad
d 
so
 m
uc
h 
bu
rd
en
 to
 th
e 
tri
al
s a
nd
 d
oe
sn
’t 
di
str
ac
t p
eo
pl
e,
 in
cl
ud
in
g 
th
e 
pa
tie
nt
s, 
fro
m
 w
ha
t t
he
 
tr
ia
l i
s a
bo
ut
. (H
ea
lth
 pr
ofe
ssi
on
al)
In
te
gr
at
in
g 
in
to
 in
fra
str
uc
tu
re
Fr
om
 a
 p
ra
gm
at
ic
 tr
ia
ls 
pe
rs
pe
ct
iv
e,
 w
e 
ar
e 
tr
yi
ng
 to
 m
in
im
iz
e 
th
e 
bu
rd
en
 o
f d
at
a 
co
lle
ct
io
n 
an
d 
us
e 
ex
ist
in
g 
in
fra
str
uc
tu
re
. A
no
th
er
 st
ak
eh
ol
de
r 
ar
e 
pe
op
le
 in
 a
dm
in
ist
ra
tiv
e 
re
gi
str
y 
ty
pe
 ro
le
s w
he
re
 it
 m
ay
 n
ot
 b
e 
re
ad
ily
 a
pp
ar
en
t t
ha
t t
he
se
 a
re
 o
ut
co
m
es
 th
at
 a
re
 n
ec
es
sa
ril
y 
re
le
v
an
t b
u
t 
ce
rt
ai
nl
y 
ne
ed
 to
 [b
e] 
tho
ug
ht 
ab
ou
t p
ro
sp
ec
tiv
el
y 
in
 th
ei
r i
m
pl
em
en
ta
tio
n.
 A
 g
oo
d 
ex
am
pl
e 
fo
r m
e 
is 
th
e 
PD
O
PP
S 
stu
dy
,
 
w
ha
te
v
er
 in
fo
rm
at
io
n 
w
e 
le
ar
n 
fro
m
 S
O
N
G
-P
D
 sh
ou
ld
 b
e 
in
co
rp
or
at
ed
. (H
ea
lth
 pr
ofe
ssi
on
al)
If 
w
e 
ar
e 
try
in
g 
to
 m
ak
e 
tr
ia
ls 
sim
pl
er
,
 
jus
t m
ak
e 
th
e 
da
ta
 c
ol
le
ct
io
n 
sim
pl
er
,
 
to
 th
e 
ex
te
nt
 th
at
 th
es
e 
th
in
gs
 c
ou
ld
 g
et
 in
co
rp
or
at
ed
 in
to
 ro
ut
in
e 
cl
in
ic
al
 c
ar
e,
 th
is 
ta
sk
 w
o
u
ld
 b
e 
m
uc
h 
ea
sie
r. 
(H
ea
lth
 pr
ofe
ssi
on
al)
If 
yo
u 
co
m
e 
up
 w
ith
 a
 se
t o
f c
ar
e 
ou
tc
om
es
 a
nd
 th
ey
’re
 a
 re
as
on
ab
ly
 sh
or
t l
ist
 a
nd
 th
ey
 a
re
 v
er
y 
sim
pl
e,
 th
at
 y
ou
 c
ou
ld
 e
m
be
d 
th
em
 in
 re
gi
str
ie
s 
so
 th
at
 ev
er
y 
6 
m
on
th
s p
at
ie
nt
s a
re
 as
ke
d 
ab
ou
t f
at
ig
ue
, M
I, 
str
ok
e,
 th
e 
da
ta
 is
 a
ll 
au
to
m
at
ic
al
ly
 re
co
rd
ed
, i
f i
t’s
 a
 v
er
y 
sm
al
l n
um
be
r, 
its
 
au
to
m
at
ic
al
ly
 in
 th
e 
el
ec
tro
ni
c 
sy
ste
m
 …
 th
e 
tri
al
s d
on
’t 
ne
ed
 to
 n
ec
es
sa
ril
y 
ha
v
e 
to
 a
sk
 th
e 
pa
tie
nt
s t
he
 w
ho
le
 ti
m
e,
 h
ow
 d
o 
yo
u 
fe
el
 fa
tig
ue
, f
ill
 
o
u
t o
ur
 q
ue
sti
on
na
ire
, i
ts 
do
ne
 a
ut
om
at
ic
al
ly
 b
y 
th
e 
nu
rs
es
 a
nd
 y
ou
 d
ow
n
lo
ad
 it
. (H
ea
lth
 pr
ofe
ssi
on
al)
3,
4,
5,
6,
7
CO
N
SO
RT
,
 
Co
ns
ol
id
at
ed
 S
ta
nd
ar
ds
 o
f R
ep
or
tin
g 
Tr
ia
ls;
 C
RF
,
 
ca
se
 r
ep
or
t f
or
m
; I
CD
, I
nt
er
na
tio
na
l C
las
sif
ic
at
io
n 
of
 D
ise
as
es
; M
I, 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 P
D
O
PP
S,
 P
er
ito
ne
al
 D
ia
ly
sis
 O
ut
co
m
es
 a
nd
 
Pr
ac
tic
e 
Pa
tte
rn
s 
St
ud
y;
 S
O
N
G
-P
D
, S
ta
nd
ar
di
ze
d 
O
ut
co
m
es
 in
 N
ep
hr
ol
og
y 
Pe
rit
on
ea
l D
ia
ly
sis
.
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Ta
bl
e 
2 
|
Im
pl
em
en
ta
tio
n 
str
at
eg
ie
s a
nd
 p
at
hw
ay
s t
hr
ou
gh
 p
ar
tn
er
sh
ip
 w
ith
 st
ak
eh
ol
de
rs
St
ra
te
gy
/p
at
hw
ay
Pr
o
fe
ss
io
na
l s
oc
ie
tie
s
C
on
su
m
er
s 
in
cl
ud
in
g 
co
ns
um
er
 
o
rg
an
iz
at
io
ns
Tr
ia
l n
et
w
o
rk
s/t
ri
al
ist
s
R
es
ea
rc
h 
fu
nd
er
s
R
eg
ul
at
or
s/p
ol
ic
ym
ak
er
s
Tr
ia
l r
eg
ist
ri
es
A
dm
in
ist
ra
tiv
e 
da
ta
se
ts
/p
at
ie
nt
 re
gi
st
ri
es
Jo
u
rn
a
ls
Ev
id
en
ce
 sy
nt
he
sis
 
gr
o
u
ps
 (g
uid
eli
ne
s, 
sy
st
em
at
ic
 re
v
ie
w
s)
Ed
uc
at
e 
ab
ou
t t
he
 n
ee
d,
 d
ef
in
iti
on
, a
nd
 p
ur
po
se
 o
f c
or
e 
ou
tc
om
es
a
●
●
●
●
●
H
ig
hl
ig
ht
 ex
am
pl
es
 o
f p
rio
r s
uc
ce
ss
 in
 im
pl
em
en
tin
g 
re
la
te
d 
in
iti
at
iv
es
 a
n
d 
im
pa
ct
s o
f c
or
e 
o
u
tc
om
es
b
●
●
Pr
ov
id
e 
tra
in
in
g 
in
 th
e 
us
e 
of
 c
or
e 
ou
tc
om
es
 (t
oo
ls,
 re
so
urc
es,
 tu
tor
ial
s)
●
●
●
●
D
em
on
st
ra
te
 fe
as
ib
ili
ty
,
 
in
 o
th
er
 w
o
rd
s, 
pi
lo
t t
es
t a
nd
 ev
al
ua
te
 u
se
 o
f c
or
e 
ou
tc
om
es
 (i
nc
lud
ing
 in
 
pr
ag
m
at
ic
 tr
ia
ls)
●
Pu
bl
ish
 o
r p
ro
v
id
e 
a 
re
fe
re
nc
e 
to
 c
or
e 
ou
tc
om
e 
se
ts
●
●
●
●
●
●
●
●
R
ec
om
m
en
d 
or
 m
an
da
te
 th
e 
us
e 
of
 c
or
e 
ou
tc
om
es
●
●
●
●
●
●
●
Em
be
d 
co
re
 o
ut
co
m
es
 in
to
 in
fra
str
uc
tu
re
 (d
ata
ba
ses
)
●
●
●
O
M
ER
AC
T,
 
O
ut
co
m
e 
M
ea
su
re
s i
n 
Rh
eu
m
at
ol
og
y.
a I
m
pr
ov
e 
co
n
sis
te
nc
y 
an
d 
re
le
v
an
ce
 o
f o
ut
co
m
es
 re
po
rte
d 
in
 tr
ia
ls;
 id
en
tif
y 
th
ro
ug
h 
a 
sy
ste
m
at
ic
 a
nd
 tr
an
sp
ar
en
t i
nt
er
na
tio
na
l c
on
se
ns
us
 p
ro
ce
ss
; a
dd
 to
 o
ut
co
m
es
 th
at
 tr
ia
lis
ts 
w
an
t t
o 
in
cl
ud
e 
in
 th
ei
r t
ria
ls 
(an
d d
oe
s n
ot 
ha
v
e 
to
 b
e 
th
e 
pr
im
ar
y 
ou
tc
om
e);
 ha
v
e 
m
ea
su
re
s 
th
at
 a
re
 
ea
sy
,
 
sim
pl
e,
 a
nd
 in
ex
pe
ns
iv
e 
to
 u
se
; i
nc
lu
de
 o
n 
th
e 
ba
sis
 o
f i
m
po
rta
nc
e 
to
 p
at
ie
nt
s a
nd
 c
ar
eg
iv
er
s 
fo
r d
ec
isi
on
 m
ak
in
g 
(no
t b
ase
d o
n e
x
pe
ct
ed
 re
sp
on
se
 to
 th
e 
in
te
rv
en
tio
n).
b I
m
pl
em
en
ta
tio
n 
of
 re
po
rti
ng
 g
ui
de
lin
es
, t
ria
l r
eg
ist
ra
tio
n;
 im
pr
ov
ed
 re
po
rti
ng
 o
f O
M
ER
AC
T 
co
re
 o
ut
co
m
es
 in
 rh
eu
m
at
oi
d 
ar
th
rit
is.
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